Cynapsus Therapeutics Inc Share Price

Stocks

Delayed Toronto S.E. Other stock markets			5-day change	1st Jan Change
- ^CAD	-.--%		+0.21%	-

06-03	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
06-03	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT

06-03	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
06-03	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT
06-03	CoTec JV, HyProMag USA, to Commence Preparatory Work for Project Execution Phase at Dallas-Fort Worth Texas Hub	MT
05-20	CoTec Releases Updated Mineral Resource and "Positive" PEA for Lac Jeannine Iron Tailings Project; Lost Near 10% on Tuesday	MT
11/03/24	Mkango and CoTec Brief: Mkango Subsidiary, Maginito, And CoTec Appointed Lead Engineers BBA And Pegasus To Complete Feasibility Study for HyProMag USA	MT
29/01/24	CoTec Holdings Outlines Key Targets For 2024	MT
03/01/24	Mkango Surges Near 12% As Forms HyProMag Joint Venture In US With CoTec	MT
10/10/23	Mkango Surges 11% As Says To Commence Feasibility Study For Proposed US Operation With CoTec	MT
10/10/23	Mkango, CoTec To Commence Feasibility Study For Proposed US Operation	MT
02/10/23	CoTec Completed Conversion of 2 Million Pounds Mkango Loan Note to Double Equity Position in Maginito to 20.6%	MT
14/09/23	Mkango Down Near 3% As Agrees To Form US Joint Venture With CoTec Holdings	MT
14/09/23	CoTec Holdings, Mkango To Form US Joint Venture	MT
30/06/23	Kings Chapel Increases Stake In CoTec Holdings	MT

05-06	COPPER INTELLIGENCE TO FORM AN EARLY-STAGE EXPLORATION JOINT VENTURE WITH COTEC TO TARGET PROCESSING HISTORICAL COPPER TAILINGS OPPORTUNITIES IN THE DEMOCRATIC REPUBLIC OF CONGO	PR
31/08/16	Cynapsus Therapeutics : Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics	PU
29/08/16	Cynapsus Therapeutics : Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL
15/08/16	Cynapsus Therapeutics : Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson's Disease Clinical Study Allowing for At-Home Titration	GL
12/08/16	Cynapsus Therapeutics : Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CYNAPSUS THERAPEUTICS INC	-.--%	+0.21%	-	-	0
ARGENX SE	+0.10%	+1.03%	+63.49%	+118.38%	55.35B
WUXI APPTEC CO., LTD.	+1.58%	+14.12%	+72.87%	+85.18%	51.92B
BIONTECH SE	-0.23%	-0.98%	-14.12%	-16.00%	22.76B
INSMED INCORPORATED	+0.98%	+9.05%	-0.36%	+423.40%	22.64B
WUXI BIOLOGICS (CAYMAN) INC.	-0.18%	+7.48%	+32.16%	-14.07%	17.36B
GENMAB A/S	-3.56%	+1.47%	+25.56%	-36.11%	16.1B
PHARMAESSENTIA CORPORATION	+3.02%	+12.74%	+143.33%	+308.04%	13.96B
EXELIXIS, INC.	+0.68%	+2.54%	+22.28%	+168.03%	13.38B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.31%	+6.52%	+28.62%	-	12.27B
Average	+0.27%	+5.82%	+41.53%	+129.61%	25.08B
Weighted average by Cap.	+0.37%	+6.54%	+46.90%	+121.43%